Vildrozon-M Tablets 50/500mg is primarily indicated in conditions like Type Il diabetes ellitus.
Vildrozon-M Tablets 50/500mg is contraindicated in conditions like Hypersensitivity to the drug.
Vildrozon-M Tablets 50/500mg produces potentially life-threatening effects which include Angioedema. which are responsible for the discontinuation of Vildrozon-M Tablets 50/500mg therapy.The signs and symptoms that are produced after the acute overdosage of Vildrozon-M Tablets 50/500mg include Muscle aches, Fever, Swelling of feet and lower legs, Mild paresthesia. The symptomatic adverse reactions produced by Vildrozon-M Tablets 50/500mg are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Asthenia, Hypoglycemia.
Do not use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. not recommended in ESRD on haemodialysis patients. Do not use in patients with hepatic impairment, including patients with pretreatment ALT or AST > 3x ULN. Liver function should be monitored during treatment with Vildrozon-M Tablets 50/500mg at three-month intervals during the first year and periodically thereafter. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue it. Following withdrawal of treatment with Vildrozon-M Tablets 50/500mg and LFT normalisation, treatment with Vildrozon-M Tablets 50/500mg should not be reinitiated. Monitoring for skin disorders, such as blistering or ulceration, is recommended while keeping with routine care of the diabetic patient.